The story
On December 29, 1987, the U.S. Food and Drug Administration approved fluoxetine, which Eli Lilly sold as Prozac from January 1988. It was a selective serotonin reuptake inhibitor, or SSRI, a drug that raises levels of the brain chemical serotonin by slowing its reabsorption by nerve cells. Prozac and the SSRIs that followed became some of the most widely used drugs for depression and anxiety.
The first antidepressants appeared by accident in the 1950s. The tuberculosis drug iproniazid, a monoamine oxidase inhibitor, lifted patients' moods, and imipramine, a tricyclic compound, followed. They worked, but they caused dry mouth, weight gain, dangerous interactions with some foods, and could be lethal in overdose. Researchers then developed the hypothesis that low activity of serotonin and similar chemical messengers played a role in depression. At Lilly in the early 1970s, Bryan Molloy, Ray Fuller and David Wong developed a compound that blocked serotonin reuptake selectively, leaving other systems alone, and the result was fluoxetine.
Prozac was easier to take than its predecessors, with a safer profile in overdose, and general practitioners could prescribe it with little monitoring. Sales grew to billions of dollars a year, and Newsweek put it on its cover in 1990. Books such as Peter Kramer's Listening to Prozac (1993) and Elizabeth Wurtzel's memoir Prozac Nation (1994) brought the drug and the discussion of depression into popular culture. Debate continues over how large the benefit is. Many studies found that SSRIs work, particularly in severe depression, but some analyses find only small average advantages over placebo in milder cases, and in 2004 regulators added warnings about suicidal thoughts in young people. Surveys by U.S. health authorities have found about one in eight American adults taking antidepressants in a given month.
Why it mattered
- SSRIs and related drugs such as sertraline became first-line treatments, and antidepressants became among the most prescribed drugs.
- Depression came to be discussed openly as a medical condition, with less stigma.
- Debates over placebo effects, overprescribing and safety in young people shaped regulation and clinical trial practice.
- Marketing of drugs to doctors and directly to patients grew as the antidepressant market expanded.
Sources
- Antidepressant Use Among Adults: United States, 2015-2018 (NCHS Data Brief 377) CDC NCHS
- FDA Approves Prozac as an Antidepressant EBSCO Research Starters
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…